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Aims There are few non-invasive techniques to predict and monitor patients’ responses to left ventricular assist device
(LVAD) therapy. MicroRNAs (miRs) are small non-coding RNAs with intricate roles in cardiovascular disease. They
are stable in the circulation, readily quantified, and may be useful as new biomarkers. This study sought to identify
candidate miR biomarkers for further investigation.
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Methods
and results
We studied 53 plasma and 20 myocardial samples from 19 patients who underwent HeartMate II LVAD implantation,
and used a screening microarray to analyse the change in expression of 1113 miRs after 6 months LVAD support.
Twelve miRs showed significant variation and underwent validation, yielding miR-1202 and miR-483-3p as candidate
biomarkers. In the test cohort, circulating miR-483-3p showed early and sustained up-regulation with LVAD support,
with median (interquartile range) fold changes from baseline of 2.17 (1.43–2.62; P= 0.011), 2.27 (1.12–2.42;
P= 0.036), 1.87 (1.64–4.36; P= 0.028), and 2.82 (0.70–10.62; P= 0.249) at 3, 6, 9, and 12 months, respectively, whilst
baseline plasma miR-1202 identified good vs. poor LVAD responders [absolute expression 1.296 (1.293–1.306) vs.
1.311 (1.310–1.318) arbitrary units; P= 0.004]. Both miRs are enriched in ventricular myocardium, suggesting the
heart as the possible source of the plasma fraction.
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Conclusions This is the first report of circulating miR biomarkers in LVAD patients.We demonstrate the feasibility of this approach,
report the potential for miR-483-3p and miR-1202, respectively, to monitor and predict response to LVAD therapy,
and propose further work to study these hypotheses and elucidate roles for miR-483-3p and miR-1202 in clinical
practice and in underlying biological processes.
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Introduction
Left ventricular assist devices (LVADs) are implantable mechanical
blood pumps that remain essential tools in patients with advanced
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.. heart failure.1 However, their use is limited by high rates of
adverse events and high cost.2,3 Appropriate patient selection
remains the key to optimizing patient outcomes, with clinical
management relying on biomarkers to assist risk stratification and
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serial monitoring. Various parameters have been characterized for
this purpose, particularly haemodynamic information from invasive
right heart catheterization, but none provides adequate sensitivity
and specificity for use as independent biomarkers.4
MicroRNAs (miRs) are tiny fragments of non-coding RNA typ-
ically 20–22 nucleotides in length, and there is accumulating evi-
dence of their intricate role in cardiac physiology and disease.5,6
Their primary biological function is post-transcriptional regulation
of gene expression by sequence-specific binding with mRNAs caus-
ing translational repression or mRNA degradation, and they might
have further roles in cell–cell interactions controlling systemic
alterations to the proteome.7 Analysis of miRs in the ventricular
myocardium of heart failure patients undergoing LVAD implanta-
tion has shown plasticity of the miR-ome8 and specific expression
patterns related to subsequent myocardial recovery and LVAD
explant vs. persistent LVAD dependency.9 In addition to expression
in the tissue of origin, miRs can be isolated from circulating blood,
where they remain extremely stable due to their transport in asso-
ciation with microvesicles and exosomes, or in tight association
with RNA-binding proteins that protect them from ribonuclease
degradation.10 These characteristics and their ready quantification
make them excellent biomarker candidates, and there are prelimi-
nary results identifying individual miRs or miR signatures for diag-
nosis of cardiovascular diseases including heart failure and acute
myocardial infarction.11–13
Circulating miRs have not been characterized in LVAD patients.
Here we hypothesize that (i) circulating miRs are candidate
biomarkers for predicting and monitoring clinical response to
LVAD implantation; and that (ii) the circulating miR pattern is
related to expression in ventricular myocardium.
Methods
Collection of human samples and clinical
parameters
Human ventricular myocardial and plasma samples were obtained from
patients who underwent implantation of a Thoratec HeartMate II
LVAD at University Hospital Leuven, Belgium between November
2009 and September 2011. All samples were collected with informed
consent and ethical approval as part of a previous research project
(study number S-52-659; ethics approval number ML-6832). Plasma
samples were obtained prior to LVAD implantation and at 3-month
intervals after LVAD support until time of cardiac transplantation.
Myocardial samples were collected at the time of LVAD implantation
and subsequent cardiac transplantation. All samples were immediately
frozen with liquid nitrogen and stored at –80 ∘C until required for
laboratory analysis. Clinical data were obtained contemporaneously
with sample collection. Assays of NT-proBNP and estimation of LVEF
were performed, respectively, by the clinical laboratories and core
echocardiography laboratory at University Hospitals Leuven, Belgium.
Total RNA isolation
All RNA studies were performed in the Institute for Molecular
and Translational Therapeutic Strategies in Hannover Medical School,
Hannover, Germany. Total RNA isolation was performed using the
Qiagen miReasy Mini Kit and 96 Kit (Qiagen, Venlo, The Netherlands) ..
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.. with QIAzol Lysis Reagent used for cell lysis. For plasma samples, a
fixed volume (200𝜇L) was used and the homogenate spiked with RNA
from Caenorhabditis elegans gene 39 (5𝜇L of 1 fmol/𝜇L RNA) as exter-
nal control. For myocardial tissue samples, the concentration of total
RNA in the final eluate was determined using ultraviolet spectroscopy,
and samples prepared each containing a fixed quantity of total RNA.
RNU48 was used as endogenous control for tissue samples.
Polymerase chain reaction microarray
for microRNA expression profiling
RNA was pooled into four pairs of samples for miR expression
profiling. cDNA was prepared for real-time quantitative polymerase
chain reaction (RT-qPCR) from these pooled samples using QuantiMir
(BioCat GmbH, Heidelberg, Germany), and miR expression profiling
was performed with the Biocat Human Genome Wide microRNA
384-well RT-qPCR Array (BioCat GmbH) using the BioRad CFX384
Touch RT qPCR Detection System (BioRad, Hemel Hempstead, UK).
This array uses SYBR Green reagents and detects 1113 known miRs
identified in the Sanger miRBase Version 15.
Validation and quantification
with TaqMan real-time quantitative
polymerase chain reaction
The miRs identified in the screening microarray were validated in indi-
vidual samples using the more specific TaqMan RT-qPCR technique.
The validated miRs were quantified in all samples using fresh prepa-
rations of total RNA isolated from all available myocardial and plasma
samples. For all these reactions, cDNA transcripts were prepared using
the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA, USA), and real-time qPCR was done using the ViiA
7 Real-Time PCR System (Applied Biosystems) using Absolute Blue
reagents. All TaqMan reactions were performed in duplicate.
Analysis of real-time quantitative
polymerase chain reaction data
For the microarray, data were normalized by two separate methods
each generating comparable results. The first method used C. elegans
spike-in reference, to control for differing efficiencies of RNA isolation
and individual qPCR runs, and the second method used global normal-
ization, whereby the mean expression data across the plate are used to
normalize individual values. After normalization, candidate miRs were
identified if they were expressed in all test samples and showed a fold
change in expression >3 times or <0.33 times between baseline and
6 months. miRs with threshold cycle (Ct) values >35 were highlighted
as unreliable. For candidate identification, fold change in expression
between baseline and 6 months was calculated for each miR, and paired
t-tests were used to identify statistically significant differences. For Taq-
Man reactions, normalization was performed using C. elegans spike-in
reference only, due to the small number of RT-qPCRs per plate. In all
cases, the selection of thresholds for detection was performed by per-
sonnel blinded to the study groups. miR quantification is expressed as
‘log.[40 – Ct value]’.
Study design and statistics
The primary outcome was change in miR expression at 6 months.
For assessment of predictive biomarkers, we classified the clinical
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Patient characteristics at the time of left ventricular assist device implantation
Whole cohort
(n= 19)
Good responders
(n= 7)
Poor responders
(n= 6)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gender, n (%)
Female 4 (21) 2 (29) 1 (17) 0.612
Male 15 (79) 5 (71) 5 (83)
Age in years, median (IQR) 52 (30–61) 40 (14–62) 55 (36–60) 0.731
Aetiology, n (%)
Ischaemic 10 (53) 2 (29) 3 (50) 0.429
Non-ischaemic 9 (47) 5 (71) 3 (50)
Body mass index (kg/m2), median (IQR) 23.4 (22.5–26.6) 22.1 (20.9–25.4) 23.3 (22.8–27.8) 0.181
Current or previous smoker, n (%) 7 (37) 1 (14) 4 (67) 0.053
Diabetes mellitus, n (%) 1 (5) 1 (14) 0 (0) 0.335
Chronic renal failure, n (%) 0 (0) 0 (0) 0 (0) –
Medications, n (%)
Intravenous inotrope 10 (53) 4 (57) 3 (50) 0.797
ACE inhibitor 12 (63) 5 (71) 4 (67) 0.853
ARB 1 (5) 0 (0) 1 (17) 0.261
Beta-blocker 11 (58) 6 (86) 3 (50) 0.164
MRA 6 (32) 0 (0) 4 (67) 0.009
Digoxin 3 (16) 3 (43) 0 (0) 0.067
Diuretic 14 (74) 5 (71) 5 (83) 0.612
Platelet inhibitor 6 (32) 2 (29) 1 (17) 0.612
Anticoagulant 0 (0) 0 (0) 0 (0) –
INTERMACS profiles 1–3, n (%) 15 (80) 6 (86) 4 (67) 0.416
NT-proBNP (ng/L), median (IQR) 4724 (1526–20 890) 17499 (4724–30 212) 1443 (1306–3858) 0.008
Change in NT-proBNP after 3 months LVAD support 0.23 (0.07–0.62) 0.08 (0.04–0.13) 0.62 (0.54–1.14) 0.001
LVEF (%), median (IQR) 15 (15–25) 20 (10–30) 15 (13–23) 0.662
Data are shown for the whole cohort and for the good and poor responder subgroups. The P-value refers to comparison of the subgroups.
IQR, interquartile range; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LVAD, left ventricular assist device; MRA, mineralocorticoid
receptor antagonist.
response to LVAD therapy based on their change in NT-proBNP at
3 months, and divided the cohort at the 50th centile for a binary
outcome. Patients whose change in NT-proBNP was above the 50th
percentile (i.e. smaller change) were identified as poor responders,
and patients whose change in NT-proBNP was below the 50th centile
(i.e. larger change) were identified as good responders. Descriptive
statistics are shown as the median (interquartile range). Final data
showed non-normal distribution, and non-parametric tests were used
for outcome analysis. All analysis was done using IBM SPSS Statistics
Version 21 with log-transformed data. Results with P< 0.05 were
considered statistically significant.
Results
Patient characteristics and clinical
response to left ventricular assist device
therapy
We retrospectively obtained 53 serial plasma and 20 ventricu-
lar myocardial samples from 19 patients with severe advanced
heart failure who underwent LVAD implantation. Patients’ base-
line characteristics are summarized in Table 1 and reflect the
advanced nature of their disease, with 80% in INTERMACS
profiles 1–3, NT-proBNP concentration 4724 (1526–20890) ng/L, .
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.. and LVEF 15 (15–25) %. These values are similar to parameters
reported in previous clinical trials, confirming that this sam-
ple is a representative LVAD population.14,15 All patients were
implanted with a HeartMate II LVAD at baseline. NT-proBNP
levels show inverse correlation with duration of LVAD support
(r= –0.508, P= 0.0001), with NT-proBNP concentration falling to
924 (653–2792) ng/L and 674 (524–1421) ng/L by 3 and 6 months,
respectively. During the study period, 15 patients (79%) under-
went cardiac transplantation after 200 (133–299) days, and at the
time of transplantation NT-proBNP was 1116 (828–2130) ng/L.
Identification of candidate biomarkers
To identify candidate miR biomarkers (Figure 1), we studied a
screening cohort for whom we had paired plasma samples from
baseline and after 6 months LVAD support (n= 8). After total
RNA isolation and cDNA synthesis, we used an RT-qPCR screening
microarray to compare differential expression of 1113 plasma miRs
in four pairs of pooled samples (see the Methods). In one of the
sample pools (n= 2), there was failure of the C. elegans spike-in
to amplify, alongside a high rate of amplification failure for other
target miRs, probably related to the presence of heparin or PCR
inhibitors. These data were excluded from the analysis, making a
final n= 6 in the screening cohort.
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Schematic diagram illustrating the strategy for identifi-
cation and validation of candidate microRNAs (miRs). For identi-
fication of candidate miRs we used a screening cohort of eight
patients with paired plasma samples from before and after 6
months of left ventricular assist device therapy. Total RNA was
extracted, and this was pooled into four test samples for each
time point. We used a real-time quantitative polymerase chain
reaction (RT-qPCR) microarray for unbiased expression profil-
ing. Amplification failed for one sample pair and therefore this
was excluded from analysis, giving a final n = 6 for the screening
cohort. The microarray yielded 12 candidate miRs. These under-
went validation using TaqMan RT-qPCR for greater specificity to
minimize false-positive results, yielding miR-1202 and miR-483-3p
as candidate miRs of interest. After fresh RNA extraction, these
two miRs were quantified in the test cohort of all 73 samples (53
plasma and 20 LV myocardial tissue). All TaqMan reactions in the
screening and test cohorts were performed in duplicate. See the
Methods for more details.
One hundred and thirteen miRs met the criteria for consider-
ation, of which 12 miRs showed statistically significant variation.
These were (fold change, P-value): miR-1254 (5.75, P< 0.01),
miR-33a (118.25, P< 0.01), miR-219-1-3p (4.15, P< 0.01),
miR-548 l (0.16, P= 0.01), miR-1250 (11.12, P= 0.02), miR-938
(121.43, P= 0.03), miR-483-3p (5.78, P= 0.03), miR-4266 (30.57, ..
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.. P= 0.03), miR-4325 (0.13, P= 0.03), miR-1202 (59.50, P= 0.03),
miR-557 (20.00, P= 0.05), and miR-1275 (5.24, P= 0.05).
For greater specificity, these findings were validated using Taq-
Man RT-qPCR in the individual samples used during the screen-
ing microarray (n= 14). miR-1202 and miR-483-3p were detected
robustly (mean Ct values across all samples were 19.365± 1.090
and 31.497±1.342 cycles, respectively) and showed change in
expression consistent with the microarray but with a lesser ampli-
tude (fold change 1.91, P= 0.10; and fold change 1.90, P= 0.11,
respectively). These lesser degrees of statistical confidence were
accepted for candidate selection at this stage, given the limitations
of the small sample size. The remaining miRs were false positives,
showing either robust expression but no significant difference, or
unreliable expression data (e.g. Ct> 35 cycles, high standard devi-
ation between duplicates).
Thus the screening yielded miR-1202 and miR-483-3p as candi-
date miR biomarkers that show significant change during 6 months
of LVAD support, and these were taken forward for further assess-
ment.
After left ventricular assist device
implantation, miR-483-3p is up-regulated
in plasma and in ventricular myocardium
Having identified two candidate biomarkers, we characterized
how their expression varied after LVAD implantation in plasma
and ventricular myocardium. We used a test cohort including all
available myocardial and plasma samples from all 19 patients. Fresh
total RNA isolation was performed, followed by quantification of
miR-1202 and miR-483-3p in all plasma and myocardial samples
using TaqMan RT-qPCR (n= 73). Of the 53 plasma samples, there
was poor amplification in two, and these were excluded. In the
remaining plasma samples (n= 51), both miRs were expressed
robustly [Ct values 19.64 (19.25–19.87) and 31.85 (31.25–32.44)
cycles for miR-1202 and miR-483-3p, respectively]. Both miRs
were strongly expressed in the ventricular myocardium [n= 20;
Ct values 21.19 (21.05–21.32) and 25.28 (24.83–25.92) cycles for
miR-1202 and miR-483-3p, respectively].
For temporal assessment of circulating miR expression, dura-
tion of LVAD support was categorized as 0 months (n=14;
before LVAD implantation), 3 months [n= 9; 91 (83–91) days after
implant], 6 months [n= 8; 187 (181–193) days], 9 months [n= 7;
271 (265–272) days], and 12 months [n= 6; 371 (361–392) days].
For comparison of plasma and myocardial expression, we stud-
ied paired samples of ventricular myocardium at baseline and after
LVAD support at the time of transplantation, and compared this
with corresponding plasma expression (n= 10 pairs).
Circulating miR-483-3p showed early and sustained
up-regulation with LVAD support, with fold changes from baseline
of 2.17 (1.43–2.62; P= 0.011), 2.27 (1.12–2.42; P= 0.036), 1.87
(1.64–4.36; P= 0.028), and 2.82 (0.70–10.62; P= 0.249) at 3, 6, 9,
and 12 months, respectively (see Table 2 and Figure 2). These results
mirrored the reduction in NT-proBNP levels [e.g. at 6 months,
fold change 0.30 (0.08–0.43; P= 0.004]. Myocardial expression of
miR-483-3p also showed up-regulation, with absolute expression
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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B
Figure 2 Temporal changes in plasma levels of
microRNA-483-3p (miR-483-3p) and plasma concentration of
NT-proBNP after implantation of a left ventricular assist device
(LVAD). There is significant early and sustained up-regulation of
plasma miR-483-3p after LVAD implantation (A), which mirrors
the reduction in levels of NT-proBNP (B). Each line represents
one patient. For miR-483-3p, data are shown for n = 14, n = 9, n
= 8, n = 7, and n = 6 for 0, 3, 6, 9, and 12 months, respectively.
For NT-proBNP, data are shown for n = 14, n = 13, n = 11, n =
9, and n = 7 for 0, 3, 6, 9. and 12 months respectively. *P < 0.05;
**P < 0.01.
increased from 1.153 (1.093–1.171) arbitrary units (AU) at the
time of LVAD implantation to 1.180 (1.167–1.191) AU at the time
of transplantation, equating to a fold change of 1.80 (0.72–4.72;
P= 0.169; Figure 3).
In contrast, detection of circulating miR-1202 showed only small
changes from baseline at all time points in the test cohort, and the
change in miR-1202 expression between baseline and 6 months
that was observed in the screening cohort was not replicated
[fold change 0.94 (0.79–1.51; P= 1.000)]. Tissue expression of
miR-1202 also showed no change with LVAD support [fold change
0.99 (0.81–1.07); P= 0.575; Figure 3].
Considering all plasma samples (n= 51), there was a trend
towards correlation between NT-proBNP levels and plasma
expression of miR-1202 (r= –0.270, P= 0.055), but no association
of NT-proBNP with miR-483-3p (P= 0.406) and no correlation
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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A B
Figure 3 Changes in myocardial expression of the microRNAs (miRs) miR-483-3p and miR-1202 between the time of left ventricular assist
device (LVAD) implantation and time of subsequent cardiac transplantation. There were paired samples from the time of LVAD implantation
and time of cardiac transplantation from 10 patients. The median time to transplantation was 200 (133–299) days. After LVAD support, there
was up-regulation of myocardial miR-483–3p expression [A, median fold change 1.799 (0.717–4.719; P = 0.169)], but no significant change in
myocardial miR-1202 expression [B, median fold change 0.988 (0.808–1.070; P = 0.575)]. Each line represents one patient.
between duration of LVAD support in days and fold change
in plasma expression of miR-483-3p (P= 0.498) or miR-1202
(P= 0.759). Despite the relationship between plasma and myocar-
dial expression for each miR, we found no direct correlation
between plasma and myocardial expression in the limited number
of patients for whom we had paired plasma–myocardial samples
(n= 10). Furthermore, there was no difference in plasma expres-
sion of either miR (miR-483-3p or miR-1202) by gender (P= 0.733,
P= 0.839) or heart failure aetiology (P= 0.282, P= 0.228).
miR-1202 as a biomarker for predicting
response to left ventricular assist device
support
We hypothesized that baseline measurement of the candidate
miRs might provide novel biomarkers that predict individual
patients’ response to LVAD support. We classified patients’ clinical
response to LVAD therapy based on their change in NT-proBNP
at 3 months (n= 13). There was a strong correlation between
baseline miR-1202 expression and change in NT-proBNP at 3
months (r= 0.604, P= 0.029). We divided the cohort at the
50th centile for change in NT-proBNP at 3 months to iden-
tify good responders (n= 7) and poor responders (n= 6; see the
Methods and Figure 4). Expression of circulating miR-1202 var-
ied significantly between these groups [1.296 (1.293–1.306) vs.
1.311 (1.310–1.318) AU; P= 0.004]. Finally, receiver operator
characteristic (ROC) curve analysis to compare baseline cir-
culating miR-1202, baseline NT-proBNP, and the pre-operative .
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.. INTERMACS profile identifies baseline miR-1202 as the best pre-
dictor of change in NT-proBNP at 3 months [(n= 13; area under
the curve (AUC) 0.976 (0.904–1.000), 0.714 (0.397–1.000), and
0.071 (0.000–0.210) for pre-implant miR-1202, INTERMACS pro-
file, and NT-proBNP respectively, P= 0.04].
Discussion
This is the first time that circulating miRs have been characterized
in heart failure patients treated with LVAD therapy. We have
performed a large-scale unbiased microarray screen and identified
novel miRs of relevance to this patient cohort. We have confirmed
the feasibility of this approach, and demonstrated the plasticity of
miR-483-3p expression in plasma and in ventricular myocardium in
response to LVAD support. Furthermore, we have shown potential
for circulating miRs to act as biomarkers for predicting (miR-1202)
and monitoring (miR-483-3p) individual patients’ response to LVAD
therapy.
The need for new biomarkers
There is a paucity of non-invasive biomarkers that assist patient
selection and serial monitoring of LVAD patients. Contemporary
risk stratification relies on an experienced clinician integrating
multiple prognostic parameters including clinical situation, maximal
oxygen uptake, levels of natriuretic peptides, results from invasive
right heart catheterization, and risk scores such as the Seattle
Heart Failure Model.1,4,16,17 After LVAD implantation there are
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 microRNA-1202 (miR-1202) identifies patients at high risk of inadequate response to left ventricular assist device (LVAD) support.
We used change in change in NT-proBNP after 3 months of LVAD support as a marker of clinical response to LVAD support (n = 13). Dividing
the cohort at the median identified good (n = 7) and poor (n = 6) responders. The scatterplot (A) and boxplot (B) show plasma miR-1202
expression before LVAD implantation, identifying good vs. poor responders. Expression of circulating miR-1202 varied significantly between
these groups [good, 1.296 (1.293–1.306) vs. poor, 1.311 (1.310–1.318) AU; P = 0.004].
inadequate tools for assessing changes in ventricular function
during ongoing support: cardiac catheterization is informative but
invasive; echocardiography studies the unloaded LV and is limited
by obstruction of apical views;18 and others such as exercise testing
and natriuretic peptides give information about overall circulatory
function yielded by the heart and pump together.19 Use of the ‘turn
down’ study, where the LVAD speed is temporarily reduced to
challenge the ventricle with volume loading, partially overcomes
this to allow functional, haemodynamic, or echocardiographic
assessments, but is time consuming and carries a theoretical risk of
LVAD thrombosis due to transiently low pump speeds.20,21 Here,
we hypothesized that circulating miRs could provide additional
non-invasive tools to aid these assessments.
Monitoring response to left ventricular
assist device therapy
This cohort of 19 patients had severely advanced heart failure
at enrolment, with 80% in INTERMACS profiles 1–3, median
NT-proBNP 4724 ng/L, and median LVEF 15%. All were implanted
with a HeartMate II LVAD with varying degrees of response,
with median NT-proBNP falling to 674 ng/L by 6 months. Circu-
lating miR-483-3p shows a significant up-regulation with LVAD
support that mirrors the suppression of NT-proBNP levels.
miR-483-3p in the ventricular myocardium is also up-regulated
with LVAD support, though to a lesser extent (and not reaching
statistical significance in this small sample). These changes in .
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. miR-483-3p expression could provide a more specific assessment
of ventricular function that complements the changes in systemic
neuroendocrine milieu recorded by serial measurement of natri-
uretic peptides. This hypothesis requires further assessment in a
larger cohort to determine how changes in miR-483-3p expression
correspond to changes in functional and haemodynamic indices,
and long-term outcomes.
Identifying the likely non-responder
The heterogeneity of clinical response to LVAD support can be
challenging, and better tools for identifying patients unlikely to ben-
efit from this invasive and expensive therapy could significantly
reduce morbidity, mortality, and treatment cost. Our data iden-
tify miR-1202 as a biomarker that predicts early response to LVAD
support. Baseline plasma miR-1202 levels correlate with change in
NT-proBNP at 3 months, and stratify the cohort into poor vs. good
responders with greater accuracy than either baseline NT-proBNP
or pre-operative INTERMACS profile, parameters which are cru-
cial aids to decision-making around the time of implant. Clinically
this would be valuable for judging the likelihood of good response
to LVAD support, such that patients identified a priori as poor LVAD
responders could be put forward for an alternative therapy such as
urgent cardiac transplantation. However, this analysis is limited by
the cohort size, and by the use of change in NT-proBNP as a surro-
gate endpoint for clinical response. In the long term, miR-1202 will
need to be validated in a larger, prospective trial with long-term
clinical outcome and survival data.
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8 A.C. Morley-Smith et al.
Strengths and limitations
The key advantage of circulating miR is that it is a non-invasive
test and as such has the capacity to improve management for this
patient cohort. This relies in turn on the stability of miRs in the
circulation and in ex vivo storage, and their ready isolation and
quantification. However, levels of circulating miRs are dependent
on multiple factors, many independent of the cardiac disease itself.
We noted two points of particular relevance here. First, the pres-
ence of heparin interferes with miR quantification,22,23 though this
is mitigated in chronic LVAD patients because they are preferen-
tially anticoagulated with warfarin. Secondly, antiplatelet medica-
tions can affect the circulating miR profile and in some patients are
commenced after LVAD implantation, though our candidates show
no overlap with the platelet-responsive targets identified recently.24
Nonetheless these factors and their implications for RNA extrac-
tion efficiency may explain our observation that miR-1202 expres-
sion showed significant variation at 6 months in the microarray
and validation steps, but not in the test cohort after re-isolation
of RNA.
It is interesting that we have not identified miRs previously char-
acterized in the heart failure or LVAD populations.8–12 Moreover
having identified novel miR candidates pertaining to this precise
clinical scenario, we chose not to include other miRs previously
associated with heart failure. There are several reasons for this.
First, our cohort represents the extreme end-stage of the heart
failure spectrum, in comparison with others studies with largely
NYHA II–III patients. Secondly, we have taken an unbiased microar-
ray screening approach, and studied a larger panel of miRs than
previous studies using rigorous candidate selection. Finally, our
microarray was designed to compare differences between baseline
and post-LVAD therapy where others studies have compared dif-
ferences between healthy controls and heart failure, and miR-ome
plasticity differs between these scenarios.
The limitations of our conclusions are reliance on a retrospec-
tive analysis of a small, heterogeneous clinical sample, and the
necessity, in the absence of superior alternatives, to use change
in NT-proBNP as a surrogate marker for treatment response.
Whilst this is not a standard outcome measure in heart failure,
there is well-established evidence of the prognostic role of natri-
uretic peptides,25 and evidence that changes in BNP after LVAD
implantation are accompanied by changes in cellular markers of
heart failure.26 These points underline the preliminary nature of
our conclusions, and the need for further confirmatory studies in
appraising these novel biomarkers for potential clinical use.
Further work
This study has forged a new avenue of enquiry in this fast moving
field, but several questions remain unaddressed. First, we have
generated hypotheses that miR-1202 and miR-483-3p could be
useful biomarkers in LVAD patients, but these need prospective
testing in larger cohorts. Secondly, based on the current data, we
cannot draw firm conclusions about the source of the circulating
miR-1202 and miR-483-3p, nor about their biological functions.We
have shown that both miRs are enriched in ventricular myocardium ..
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.. as well as in circulating plasma, but this does not establish the
heart as the origin of the circulating fraction. Further studies in
animal models of heart failure and in human patients could include
tissue fractionation studies to identify the cellular origins of these
miRs, and functional studies to consider both local functions at
the cell or tissue level in the heart and paracrine-type signalling
to other organs through plasma expression. Finally, the plasticity
of the miR-ome may vary between different modes (e.g. pulsatile
vs. continuous flow devices) and degrees (e.g. full vs. partial) of
mechanical circulatory support which alter the quality of blood
flow. For example, we know that the vascular endothelial cell
miR-ome can be modulated by shear stress,27 and other cells
such as cardiomyocytes exhibit similar mechanosensitivity likely to
involve miR pathways. These factors combined may yield a unique
circulating miR-ome dependent on the quality of blood flow after
LVAD implantation.
Conclusion
There is an unmet need for non-invasive techniques for use in
serial assessment of LVAD patients, and this requirement is likely to
grow. We have demonstrated the feasibility of circulating miRs as
biomarkers in this patient group and proposed specific candidates
that warrant further evaluation for potential clinical use.
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